Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: experienced (1000), adept (3), accomplished (7), trained (491), expert (202)

Papers-CoG 26.04.2023

Description: Agenda attachments 1 CoG Agenda - 26.04.2023.docx Date Time Location Chair Agenda Council of Governors 26/04/2023 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-26.04.2023.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

MyelomaBortezomib SC DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (SC)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

Apply to court

Description: In clinical practice, decisions relating to adults who lack capacity are ubiquitous, both to relation to the need for new treatment
Url: /HealthProfessionals/Clinical-law-updates/Apply-to-court.aspx

Guide to the Mental Capacity Act - patient information

Description: This leaflet provides an overview of the Mental Capacity Act 2005.
Url: /Media/UHS-website-2019/Patientinformation/Visitinghospital/Guide-to-the-Mental-Capacity-Act-2865-PIL.pdf

Institutional information_2022-23_final

Description: Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application to avoid the same document
Url: /Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2022-23-final.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information contact: Chris Stock Head of R&D communications
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

Ibrutinib-Venetoclax

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia IBRUTINIB-VENETOCLAX Regimen CLL – Ibrutinib & Venetoclax Indication • Ibrutinib plus Venetoclax is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib-Venetoclax-Ver1.1.pdf

University Hospital Southampton NHS FT Audit Certificate 2024-25 - Signed 19.12.25

Description: Independent auditor’s report to the members of the Council of Governors of University Hospital Southampton NHS Foundation Trust Audit completion
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/University-Hospital-Southampton-NHS-FT-Audit-Certificate-2024-25-Signed-19.12.25.pdf

81 to 90 of 609

Previous … 7 8 9 10 11 … Next